The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•30 March 2026•

1 min read

UroGen Pharma Reports Strong Long-Term Results for Bladder Cancer Treatment ZUSDURI

Key Facts

1The Journal of Urology published the ENVISION trial results for UroGen Pharma's ZUSDURI.

2The drug achieved a 79.6% complete response rate at 3 months.

UroGen Pharma Ltd. (URGN) announced the publication of Phase 3 ENVISION trial results for its bladder cancer treatment, ZUSDURI (UGN-102). The findings, published in The Journal of Urology, highlight a significant 79.6% complete response rate within the first three months of treatment. Long-term data from the Kaplan-Meier analysis indicated a 72.2% probability of patients remaining event-free at the 24-month mark. This durability of response is a critical milestone for the company as it seeks regulatory approval for the drug in treating low-grade non-muscle invasive bladder cancer (NMIBC). The peer-reviewed publication validates the clinical efficacy of ZUSDURI, potentially positioning it as a leading non-surgical alternative. Analysts view these results as a positive catalyst for the stock, reinforcing its competitive profile in the oncology market.